HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
24
09
2021
pubmed:
27
10
2021
medline:
21
1
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
Pre-exposure prophylaxis (PrEP) has revolutionized HIV prevention, but PrEP does not protect against other sexually transmitted infections (STIs). Rates of STIs are rising worldwide, with notably high incidences among PrEP-using men who have sex with men in high-income countries; in low-income and middle-income countries, data are sparse, but results from a limited number of studies among African women initiating and taking PrEP have shown high STI prevalence and incidence. Efforts aimed at markedly reducing HIV in populations worldwide include a major focus on increasing PrEP use, along with improving HIV testing and treatment in order to eliminate HIV transmission. Together, these efforts could augment continued expansion of the global STI epidemic, but they could alternatively create an opportunity to improve STI control, including the development of comprehensive sexual health programmes and research to develop new STI prevention strategies. The introduction of PrEP globally has been characterized by challenges and many successes, and its role as part of a range of robust strategies to reduce HIV infections is clear. Looking ahead, understanding rising rates of curable STIs and their relationship to HIV prevention, and considering the future directions for synergies in PrEP and STI prevention will be integral to improving sexual health.
Identifiants
pubmed: 34697493
doi: 10.1038/s41585-021-00527-4
pii: 10.1038/s41585-021-00527-4
pmc: PMC9249100
mid: NIHMS1813037
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-15Subventions
Organisme : NIMH NIH HHS
ID : K23 MH124466
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145971
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States
Informations de copyright
© 2021. Springer Nature Limited.
Références
Blackwell, C. W. Preventing HIV infection in high-risk adolescents using preexposure prophylaxis (PrEP). J. Assoc. Nurses AIDS Care 29, 770–774 (2018).
pubmed: 30146018
doi: 10.1016/j.jana.2018.06.001
Hosek, S. G. et al. An HIV preexposure prophylaxis demonstration project and safety study for young MSM. J. Acquir. Immune Defic. Syndr. 74, 21–29 (2017).
pubmed: 27632233
pmcid: 5140725
doi: 10.1097/QAI.0000000000001179
Centers for Disease Control. Preexposure prophylaxis for the prevention of HIV infection in the United States — 2017 Update: a clinical practice guideline (CDC, 2017).
WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV (WHO, 2015).
Owens, D. K. et al. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA 321, 2203–2213 (2019).
pubmed: 31184747
doi: 10.1001/jama.2019.6390
Cairns, G., McCormack, S. & Molina, J. M. The European preexposure prophylaxis revolution. Curr. Opin. HIV AIDS 11, 74–79 (2016).
pubmed: 26599164
pmcid: 4888928
doi: 10.1097/COH.0000000000000223
Wright, E. et al. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. J. Virus Erad. 4, 143–159 (2018).
pubmed: 30050676
pmcid: 6038129
doi: 10.1016/S2055-6640(20)30260-0
Sax, P. E. et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J. Acquir. Immune Defic. Syndr. 67, 52–58 (2014).
pubmed: 24872136
doi: 10.1097/QAI.0000000000000225
Gupta, S. K. et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS 33, 1455–1465 (2019).
pubmed: 30932951
doi: 10.1097/QAD.0000000000002223
Hare, C. B. et al. The Phase 3 Discover Study: Daily F/TAF or F/TDF for HIV PrEP (CROI, 2019).
Anderson, P. L. et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl Med. 4, 151ra125 (2012).
pubmed: 22972843
pmcid: 3721979
doi: 10.1126/scitranslmed.3004006
Baeten, J. M. et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect. Dis. 14, 1055–1064 (2014).
pubmed: 25300863
pmcid: 4252589
doi: 10.1016/S1473-3099(14)70937-5
Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).
pubmed: 22784037
pmcid: 3770474
doi: 10.1056/NEJMoa1108524
Nguyen, V. K. et al. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV. AIDS 32, 523–530 (2018).
pubmed: 29239887
doi: 10.1097/QAD.0000000000001718
Traeger, M. W. et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 321, 1380–1390 (2019).
pubmed: 30964528
pmcid: 6459111
doi: 10.1001/jama.2019.2947
Morton, J. et al. High prevalence of curable STIs among young women initiating PrEP in Kenya and South Africa. in AIDS 2018: 22nd International AIDS Conference (Abstract WEPEC224) (AIDS, 2019).
Garrett, N. et al. Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional study. BMJ Open 9, e026888 (2019).
pubmed: 30782948
pmcid: 6367982
doi: 10.1136/bmjopen-2018-026888
Stewart, J., Bukusi, E., Celum, C., Delany-Moretlwe, S. & Baeten, J. M. Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention. AIDS 34, 651–658 (2020).
pubmed: 32167988
doi: 10.1097/QAD.0000000000002472
Eisinger, R. W., Erbelding, E. & Fauci, A. S. Refocusing research on sexually transmitted infections. J. Infect. Dis. 222, 1432–1432 (2019).
pmcid: 7529043
doi: 10.1093/infdis/jiz442
Stack, L. Sexually transmitted disease cases reach a record high (The New York Times, 2019).
Ryom, L. et al. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Med. 21, 617–624 (2020).
pubmed: 32885559
pmcid: 7754379
doi: 10.1111/hiv.12878
Günthard, H. F. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 316, 191–210 (2016).
pubmed: 27404187
pmcid: 5012643
doi: 10.1001/jama.2016.8900
FDA. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic (FDA News Release, 2019).
Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).
pubmed: 21091279
pmcid: 3079639
doi: 10.1056/NEJMoa1011205
Donnell, D. et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J. Acquir. Immune Defic. Syndr. 66, 340–348 (2014).
pubmed: 24784763
pmcid: 4059553
doi: 10.1097/QAI.0000000000000172
Haberer, J. E. et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 10, e1001511 (2013).
pubmed: 24058300
pmcid: 3769210
doi: 10.1371/journal.pmed.1001511
Colby, D. J. et al. Acquisition of multidrug-resistant human immunodeficiency virus type 1 infection in a patient taking preexposure prophylaxis. Clin. Infect. Dis. 67, 962–964 (2018).
pubmed: 29961859
pmcid: 6117447
doi: 10.1093/cid/ciy321
Markowitz, M. et al. Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis. J. Acquir. Immune Defic. Syndr. 76, e104–e106 (2017).
pubmed: 29076941
pmcid: 5792163
doi: 10.1097/QAI.0000000000001534
Peterson, L. et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin. Trials 2, e27 (2007).
pubmed: 17525796
pmcid: 1876601
doi: 10.1371/journal.pctr.0020027
WHO. WHO Implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection (World Health Organization, 2017).
Seifert, S. M. et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin. Infect. Dis. 60, 804–810 (2015).
pubmed: 25409469
doi: 10.1093/cid/ciu916
Saag, M. S. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA 320, 379–396 (2018).
pubmed: 30043070
pmcid: 6415748
doi: 10.1001/jama.2018.8431
Molina, J. M. et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 4, e402–e410 (2017).
pubmed: 28747274
doi: 10.1016/S2352-3018(17)30089-9
Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 Infection. N. Engl. J. Med. 373, 2237–2246 (2015).
pubmed: 26624850
doi: 10.1056/NEJMoa1506273
DeJesus, E. et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Res. Hum. Retroviruses 34, 337–342 (2018).
pubmed: 29368537
doi: 10.1089/aid.2017.0203
Daar, E. S. et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 5, e347–e356 (2018).
pubmed: 29925490
doi: 10.1016/S2352-3018(18)30091-2
WHO. What’s the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: Update to WHO’s recommendation on oral PrEP (WHO, 2019).
Thompson, C. G., Cohen, M. S. & Kashuba, A. D. Antiretroviral pharmacology in mucosal tissues. J. Acquir. Immune Defic. Syndr. 63 (Suppl. 2), S240–S247 (2013).
pubmed: 23764642
pmcid: 3951793
doi: 10.1097/QAI.0b013e3182986ff8
Karim, S. S., Kashuba, A. D., Werner, L. & Karim, Q. A. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378, 279–281 (2011).
pubmed: 21763939
pmcid: 3652579
doi: 10.1016/S0140-6736(11)60878-7
Pyra, M. et al. Patterns of oral PrEP adherence and HIV risk among eastern African Women in HIV serodiscordant partnerships. AIDS Behav. 22, 3718–3725 (2018).
pubmed: 30006791
pmcid: 6330257
doi: 10.1007/s10461-018-2221-3
Mullins, T. L. K. & Lehmann, C. E. Oral pre-exposure prophylaxis (PrEP) for HIV prevention in adolescents and young adults. Curr. Pediatr. Rep. 6, 114–122 (2018).
pubmed: 30345163
pmcid: 6192052
doi: 10.1007/s40124-018-0163-x
Were, E. O. et al. Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. AIDS 28, 1977–1982 (2014).
pubmed: 25259704
doi: 10.1097/QAD.0000000000000313
Fonner, V. A. et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30, 1973–1983 (2016).
pubmed: 27149090
doi: 10.1097/QAD.0000000000001145
Arribas, J. R. et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J. Acquir. Immune Defic. Syndr. 47, 74–78 (2008).
pubmed: 17971715
doi: 10.1097/QAI.0b013e31815acab8
Mugwanya, K. et al. Low risk of proximal tubular dysfunction associated with emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis in men and women. J. Infect. Dis. 214, 1050–1057 (2016).
pubmed: 27029778
pmcid: 5021224
doi: 10.1093/infdis/jiw125
Mulligan, K. et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis. 61, 572–580 (2015).
pubmed: 25908682
pmcid: 4565984
doi: 10.1093/cid/civ324
Grohskopf, L. A. et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J. Acquir. Immune Defic. Syndr. 64, 79–86 (2013).
pubmed: 23466649
doi: 10.1097/QAI.0b013e31828ece33
Pilkington, V., Hill, A., Hughes, S., Nwokolo, N. & Pozniak, A. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J. Virus Erad. 4, 215–224 (2018).
pubmed: 30515300
pmcid: 6248833
doi: 10.1016/S2055-6640(20)30312-5
AVAC. Global PrEP Tracker. AVAC https://www.prepwatch.org/resource/global-prep-tracker/ (2019).
County of Santa Clara Public Health Department. HIV Epidemiology Annual Report: County of Santa Clara, 2018. County of Santa Clara https://publichealth.sccgov.org/sites/g/files/exjcpb916/files/hiv-annual-report-2018.PDF (2019).
Grulich, A. E. et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 5, e629–e637 (2018).
pubmed: 30343026
doi: 10.1016/S2352-3018(18)30215-7
Finlayson, T. et al. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men — 20 urban areas, 2014 and 2017. MMWR 68, 597–603 (2019).
pubmed: 31298662
pmcid: 6741853
Calabrese, S. K. et al. Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. J. Acquir. Immune Defic. Syndr. 81, 395–405 (2019).
pubmed: 30973543
pmcid: 6594908
doi: 10.1097/QAI.0000000000002042
Siegler, A. J. et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann. Epidemiol. 28, 841–849 (2018).
pubmed: 29983236
pmcid: 6286209
doi: 10.1016/j.annepidem.2018.06.005
Poteat, T. et al. A gap between willingness and uptake: findings from mixed methods research on HIV prevention among Black and Latina transgender women. J. Acquir. Immune Defic. Syndr. 82, 131140 (2019).
doi: 10.1097/QAI.0000000000002112
Huang, Y. A., Zhu, W., Smith, D. K., Harris, N. & Hoover, K. W. HIV preexposure prophylaxis, by race and ethnicity — United States, 2014–2016. MMWR 67, 1147–1150 (2018).
pubmed: 30335734
pmcid: 6193685
Hoots, B. E., Finlayson, T., Nerlander, L. & Paz-Bailey, G., National HIV Behavioral Surveillance Study Group. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men — 20 US Cities, 2014. Clin. Infect. Dis. 63, 672–677 (2016).
pubmed: 27282710
doi: 10.1093/cid/ciw367
Hess, K. L., Hu, X., Lansky, A., Mermin, J. & Hall, H. I. Lifetime risk of a diagnosis of HIV infection in the United States. Ann. Epidemiol. 27, 238–243 (2017).
pubmed: 28325538
pmcid: 5524204
doi: 10.1016/j.annepidem.2017.02.003
Sullivan, P. S. et al. Explaining racial disparities in HIV incidence in black and white men who have sex with men in Atlanta, GA: a prospective observational cohort study. Ann. Epidemiol. 25, 445–454 (2015).
pubmed: 25911980
pmcid: 4433604
doi: 10.1016/j.annepidem.2015.03.006
Raifman, J. R. et al. Brief report: pre-exposure prophylaxis awareness and use among cisgender women at a sexually transmitted disease clinic. J. Acquir. Immune Defic. Syndr. 80, 36–39 (2019).
pubmed: 30531295
pmcid: 6293982
doi: 10.1097/QAI.0000000000001879
AVAC. Country Updates — PrEPWatch. AVAC https://www.prepwatch.org/in-practice/country-updates/ (2018).
UNAIDS. Trend of New HIV Infections. UNAIDS https://aidsinfo.unaids.org (2019).
Celum, C. L. et al. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J. Int. AIDS Soc. 22 (Suppl. 4), e25298 (2019).
pubmed: 31328444
pmcid: 6643076
UNAIDS. The Gap Report. UNAIDS https://www.unaids.org/en/resources/campaigns/2014gapreport (2015).
UNAIDS. UNAIDS Data 2018. UNAIDS https://www.unaids.org/en/resources/documents/2018/unaids-data-2018 (2018).
PrEP Watch. PrEP-it Pilot User Guide. Version 1.0. prepwatch.org https://www.prepwatch.org/wp-content/uploads/2019/09/PrEP-it_UserGuide_Sept2019.pdf (2019).
Vandepitte, J. et al. Estimates of the number of female sex workers in different regions of the world. Sex. Transm. Infect. 82 (Suppl. 3), iii18–iii25 (2006).
pubmed: 16735288
pmcid: 2576726
Golub, S. A., Gamarel, K. E., Rendina, H. J., Surace, A. & Lelutiu-Weinberger, C. L. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS 27, 248–254 (2013).
pubmed: 23565928
pmcid: 3624632
doi: 10.1089/apc.2012.0419
Hosek, S. G. et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 171, 1063–1071 (2017).
pubmed: 28873128
pmcid: 5710370
doi: 10.1001/jamapediatrics.2017.2007
Kapadia, S. N. et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Med. 6, 2050312118816919 (2018).
pubmed: 30574301
pmcid: 6295695
doi: 10.1177/2050312118816919
Hanna, D. B. et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J. Acquir. Immune Defic. Syndr. 65, 587–596 (2014).
pubmed: 24326606
pmcid: 3999284
doi: 10.1097/QAI.0000000000000082
Rodger, A. J. et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316, 171–181 (2016).
pubmed: 27404185
doi: 10.1001/jama.2016.5148
Rodger, A. J. et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 393, 2428–2438 (2019).
pubmed: 31056293
pmcid: 6584382
doi: 10.1016/S0140-6736(19)30418-0
Closson, E. F. et al. Intimacy versus isolation: a qualitative study of sexual practices among sexually active HIV-infected patients in HIV care in Brazil, Thailand, and Zambia. PLoS ONE 10, e0120957 (2015).
pubmed: 25793283
pmcid: 4368566
doi: 10.1371/journal.pone.0120957
Bearinger, L. H., Sieving, R. E., Ferguson, J. & Sharma, V. Global perspectives on the sexual and reproductive health of adolescents: patterns, prevention, and potential. Lancet 369, 1220–1231 (2007).
pubmed: 17416266
doi: 10.1016/S0140-6736(07)60367-5
Hoornenborg, E. et al. Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use: results from the Amsterdam pre-exposure prophylaxis demonstration project. AIDS 32, 1527–1532 (2018).
pubmed: 29762169
doi: 10.1097/QAD.0000000000001874
Newcomb, M. E., Mongrella, M. C., Weis, B., McMillen, S. J. & Mustanski, B. Partner disclosure of PrEP use and undetectable viral load on geosocial networking apps: frequency of disclosure and decisions about condomless sex. J. Acquir. Immune Defic. Syndr. 71, 200–206 (2016).
pubmed: 26761520
pmcid: 4712713
doi: 10.1097/QAI.0000000000000819
Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493–505 (2011).
pubmed: 21767103
pmcid: 3200068
doi: 10.1056/NEJMoa1105243
Koester, K. et al. Risk, safety and sex among male PrEP users: time for a new understanding. Cult. Health Sex. 19, 1301–1313 (2017).
pubmed: 28415911
doi: 10.1080/13691058.2017.1310927
Centers for Disease Control. HIV Incidence: Estimated Annual Infections in the U.S., 2010–2016. CDC https://www.cdc.gov/nchhstp/newsroom/2019/HIV-incidence.html (2019).
Brown, A. E. et al. Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)? Eur. Surveill. 22, 30553 (2017).
doi: 10.2807/1560-7917.ES.2017.22.25.30553
Carlo Hojilla, J. et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 20, 1461–1469 (2016).
pubmed: 25835463
doi: 10.1007/s10461-015-1055-5
Grant, R. M. & Koester, K. A. What people want from sex and preexposure prophylaxis. Curr. Opin. HIV AIDS 11, 3–9 (2016).
pubmed: 26569183
pmcid: 6446930
doi: 10.1097/COH.0000000000000216
Lal, L. et al. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS 31, 1709–1714 (2017).
pubmed: 28700394
doi: 10.1097/QAD.0000000000001519
Montano, M. A. et al. Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav. 23, 548–555 (2019).
pubmed: 30117076
pmcid: 6368873
doi: 10.1007/s10461-018-2252-9
Liu, A. Y. et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern. Med. 176, 75–84 (2016).
pubmed: 26571482
pmcid: 5042323
doi: 10.1001/jamainternmed.2015.4683
Heffron, R. et al. Objective measurement of inaccurate condom use reporting among women using depot medroxyprogesterone acetate for contraception. AIDS Behav. 21, 2173–2179 (2017).
pubmed: 27699594
pmcid: 5378697
doi: 10.1007/s10461-016-1563-y
Sander, P. M., Raymond, E. G. & Weaver, M. A. Emergency contraceptive use as a marker of future risky sex, pregnancy, and sexually transmitted infection. Am. J. Obstet. Gynecol. 201, 146.e1–6 (2009).
doi: 10.1016/j.ajog.2009.05.015
Kasaie, P. et al. The impact of preexposure prophylaxis among men who have sex with men: an individual-based model. J. Acquir. Immune Defic. Syndr. 75, 175–183 (2017).
pubmed: 28498144
pmcid: 5488295
doi: 10.1097/QAI.0000000000001354
Eisinger, R. W. & Fauci, A. S. Ending the HIV/AIDS Pandemic(1). Emerg. Infect. Dis. 24, 413–416 (2018).
pubmed: 29460740
pmcid: 5823353
doi: 10.3201/eid2403.171797
McManus, H. et al. STI trends following PrEP uptake in men who have sex with men in a population-based implementation project. JAMA Netw. Open 3, e2030806 (2020).
pubmed: 33355675
pmcid: 7758809
doi: 10.1001/jamanetworkopen.2020.30806
Centers for Disease Control. New CDC analysis shows steep and sustained increases in STDs in recent years. CDC https://www.cdc.gov/media/releases/2018/p0828-increases-in-stds.html (2018).
Newman, L. et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE 10, e0143304 (2015).
pubmed: 26646541
pmcid: 4672879
doi: 10.1371/journal.pone.0143304
Katz, D. A., Dombrowski, J. C., Bell, T. R., Kerani, R. P. & Golden, M. R. HIV incidence among men who have sex with men after diagnosis with sexually transmitted infections. Sex. Transm. Dis. 43, 249–254 (2016).
pubmed: 26967302
pmcid: 4789769
doi: 10.1097/OLQ.0000000000000423
Tilchin, C. et al. Human immunodeficiency virus diagnosis after a syphilis, gonorrhea, or repeat diagnosis among males including non-men who have sex with men: what is the incidence? Sex. Transm. Dis. 46, 271–277 (2019).
pubmed: 30870326
doi: 10.1097/OLQ.0000000000000964
Fleming, D. T. & Wasserheit, J. N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 75, 3–17 (1999).
pubmed: 10448335
pmcid: 1758168
doi: 10.1136/sti.75.1.3
Ong, J. J. et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw. Open 2, e1917134 (2019).
pubmed: 31825501
pmcid: 6991203
doi: 10.1001/jamanetworkopen.2019.17134
Ramchandani, M. S. & Golden, M. R. Confronting rising STIs in the Era of PrEP and treatment as prevention. Curr. HIV/AIDS Rep. 16, 244–256 (2019).
pubmed: 31183609
pmcid: 6582987
doi: 10.1007/s11904-019-00446-5
Comninos, N. B. et al. Increases in pharyngeal Neisseria gonorrhoeae positivity in men who have sex with men, 2011–2015: observational study. Sex. Transm. Infect. 96, 432–435 (2020).
pubmed: 31624177
doi: 10.1136/sextrans-2019-054107
Martin-Sanchez, M. et al. Trends and differences in sexual practices and sexually transmitted infections in men who have sex with men only (MSMO) and men who have sex with men and women (MSMW): a repeated cross-sectional study in Melbourne, Australia. BMJ Open 10, e037608 (2020).
pubmed: 33234617
pmcid: 7689083
doi: 10.1136/bmjopen-2020-037608
Pagkas-Bather, J., Khosropour, C. M., Golden, M. R., Thibault, C. & Dombrowski, J. C. Population-level effectiveness of HIV pre-exposure prophylaxis among MSM and transgender persons with bacterial sexually transmitted infections. J. Acquir. Immune Defic. Syndr. 87, 769–775 (2021).
pubmed: 33538527
pmcid: 8126498
doi: 10.1097/QAI.0000000000002646
Rolle, C. P. et al. Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia. Int. J. STD AIDS 28, 849–857 (2017).
pubmed: 28632468
doi: 10.1177/0956462416675095
Rojas Castro, D., Delabre, R. M. & Molina, J. M. Give PrEP a chance: moving on from the “risk compensation” concept. J. Int. AIDS Soc. 22 (Suppl. 6), e25351 (2019).
pubmed: 31468693
pmcid: 6715948
Atkins, D. N. & Bradford, W. D. Association between increased emergency contraception availability and risky sexual practices. Health Serv. Res. 50, 809–829 (2015).
pubmed: 25367046
doi: 10.1111/1475-6773.12251
Schuster, M. A., Bell, R. M., Berry, S. H. & Kanouse, D. E. Impact of a high school condom availability program on sexual attitudes and behaviors. Fam. Plann. Perspect. 30, 67–72, 88 (1998).
pubmed: 9561871
doi: 10.2307/2991662
Traeger, M. W. et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin. Infect. Dis. 67, 676–686 (2018).
pubmed: 29509889
doi: 10.1093/cid/ciy182
Montano, M. A. et al. Differences in sexually transmitted infection risk comparing preexposure prophylaxis users and propensity score matched historical controls in a clinic setting. AIDS 33, 1773–1780 (2019).
pubmed: 31149948
doi: 10.1097/QAD.0000000000002281
Holt, M. et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. Lancet HIV 5, e448–e456 (2018).
pubmed: 29885813
doi: 10.1016/S2352-3018(18)30072-9
World Health Organization, Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. WHO https://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/ (2012).
Moore, M. S., Golden, M. R., Scholes, D. & Kerani, R. P. Assessing trends in chlamydia positivity and gonorrhea incidence and their associations with the incidence of pelvic inflammatory disease and ectopic pregnancy in Washington state, 1988–2010. Sex. Transm. Dis. 43, 2–8 (2016).
pubmed: 26656441
doi: 10.1097/OLQ.0000000000000352
Brill, J. R. Diagnosis and treatment of urethritis in men. Am. Fam. Physician 81, 873–878 (2010).
pubmed: 20353145
Centers for Disease Control. Sexually Transmitted Disease Surveillance 2019. CDC https://www.cdc.gov/std/statistics/2019/default.htm (2021).
Centers for Disease Control. Sexually Transmitted Disease Surveillance 2018: Syphilis. CDC https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf (2019).
Bradley, H., Markowitz, L. E., Gibson, T. & McQuillan, G. M. Seroprevalence of herpes simplex virus types 1 and 2 — United States, 1999–2010. J. Infect. Dis. 209, 325–333 (2014).
pubmed: 24136792
doi: 10.1093/infdis/jit458
Celum, C. et al. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann. Intern. Med. 161, 11–19 (2014).
pubmed: 24979446
doi: 10.7326/M13-2471
Zemouri, C. et al. The performance of the vaginal discharge syndromic management in treating vaginal and cervical infection: a systematic review and meta-analysis. PLoS ONE 11, e0163365 (2016).
pubmed: 27706174
pmcid: 5052075
doi: 10.1371/journal.pone.0163365
Stewart, J. & Stekler, J. D. How to incorporate HIV PrEP into your practice. J. Fam. Pract. 68, 254–261 (2019).
pubmed: 31287442
Wood, B. R. et al. Knowledge, practices, and barriers to HIV preexposure prophylaxis prescribing among Washington state medical providers. Sex. Transm. Dis. 45, 452–458 (2018).
pubmed: 29465664
doi: 10.1097/OLQ.0000000000000781
Siegler, A. J. et al. Developing and assessing the feasibility of a home-based preexposure prophylaxis monitoring and support program. Clin. Infect. Dis. 68, 501–504 (2019).
pubmed: 29982304
doi: 10.1093/cid/ciy529
Gichangi, A. et al. Impact of HIV self-test distribution to male partners of ANC clients: results of a randomized controlled trial in Kenya. J. Acquir. Immune Defic. Syndr. 79, 467–473 (2018).
pubmed: 30148731
pmcid: 6250253
doi: 10.1097/QAI.0000000000001838
Mulubwa, C. et al. Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities. Lancet HIV 6, e81–e92 (2019).
pubmed: 30584047
doi: 10.1016/S2352-3018(18)30258-3
Ogale, Y., Yeh, P. T., Kennedy, C. E., Toskin, I. & Narasimhan, M. Self-collection of samples as an additional approach to deliver testing services for sexually transmitted infections: a systematic review and meta-analysis. BMJ Glob. Health 4, e001349 (2019).
pubmed: 31139454
pmcid: 6509609
doi: 10.1136/bmjgh-2018-001349
Widdice, L. E. et al. Performance of the atlas genetics rapid test for chlamydia trachomatis and women’s attitudes toward point-of-care testing. Sex. Transm. Dis. 45, 723–727 (2018).
pubmed: 29771869
pmcid: 6179923
doi: 10.1097/OLQ.0000000000000865
WHO. Global health sector strategy on sexually transmitted infections 2016–2021 towards ending STIs. WHO Bulletin https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/ (2021).
Kissinger, P. et al. Effectiveness of patient delivered partner medication for preventing recurrent Chlamydia trachomatis. Sex. Transm. Infect. 74, 331–333 (1998).
pubmed: 10195027
pmcid: 1758141
doi: 10.1136/sti.74.5.331
Golden, M. R. et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N. Engl. J. Med. 352, 676–685 (2005).
pubmed: 15716561
doi: 10.1056/NEJMoa041681
Otieno, F. O. et al. Evaluation of syndromic management of sexually transmitted infections within the Kisumu Incidence Cohort Study. Int. J. STD AIDS 25, 851–859 (2014).
pubmed: 24516075
pmcid: 4586058
doi: 10.1177/0956462414523260
Verwijs, M. C. et al. Targeted point-of-care testing compared with syndromic management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic accuracy study. Lancet Infect. Dis. 19, 658–669 (2019).
pubmed: 31031172
doi: 10.1016/S1473-3099(18)30724-2
National AIDS & STI Control Program, Ministry of Health Kenya. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya. National AIDS & STI Control Program https://faces.ucsf.edu/sites/g/files/tkssra4711/f/Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf (2018).
Van Der Pol, B. et al. Evaluation of the performance of a point-of-care test for chlamydia and gonorrhea. JAMA Netw. Open 3, e204819 (2020).
doi: 10.1001/jamanetworkopen.2020.4819
Juneja, S., Gupta, A., Moon, S. & Resch, S. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP). PLoS ONE 12, e0177770 (2017).
pubmed: 28542239
pmcid: 5444652
doi: 10.1371/journal.pone.0177770
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02720094 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03164564 (2020).
Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595–608 (2021).
pubmed: 34379922
doi: 10.1056/NEJMoa2101016
National Institutes of Health. NIH study finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women. NIH https://www.nih.gov/news-events/news-releases/nih-study-finds-long-acting-injectable-drug-prevents-hiv-acquisition-cisgender-women (2020).
WHO. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. WHO https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection (2021).
Sitruk-Ware, R., Nath, A. & Mishell, D. R. Jr Contraception technology: past, present and future. Contraception 87, 319–330 (2013).
pubmed: 22995540
doi: 10.1016/j.contraception.2012.08.002
Gottlieb, S. L. et al. Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 38, 4362–4373 (2020).
pubmed: 32359875
pmcid: 7273195
doi: 10.1016/j.vaccine.2020.02.073
Kenyon, C., Van Dijck, C. & Florence, E. Facing increased sexually transmitted infection incidence in HIV preexposure prophylaxis cohorts: what are the underlying determinants and what can be done? Curr. Opin. Infect. Dis. 33, 51–58 (2020).
pubmed: 31789694
doi: 10.1097/QCO.0000000000000621
Molina, J. M. et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect. Dis. 18, 308–317 (2018).
pubmed: 29229440
doi: 10.1016/S1473-3099(17)30725-9
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03980223 (2021).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04050540 (2021).
Petousis-Harris, H. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603–1610 (2017).
pubmed: 28705462
doi: 10.1016/S0140-6736(17)31449-6
US National Library of Medicine ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03926728 (2021).
Brenchley, J. M., Price, D. A. & Douek, D. C. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235–239 (2006).
pubmed: 16482171
doi: 10.1038/ni1316
Deeks, S. et al. HIV infection. Nat. Rev. Dis. Prim. 1, 15035 (2015).
pubmed: 27188527
doi: 10.1038/nrdp.2015.35